News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Barinthus Biotherapeutics plc. (BRNS) reported a narrower comprehensive loss in the 2026 quarter, driven by cost reductions and pipeline reprioritization towards immunology and inflammation programs. The company also completed enrollment for a Phase 1 clinical trial and entered a merger agreement with Clywedog, with …
Barinthus Bio announced its second quarter 2026 financial results and provided updates on corporate developments, including the progressing proposed combination with Clywedog Therapeutics Inc. The company completed enrollment for the Phase 1 AVALON trial of VTP-1000 for celiac disease, with topline data expected in …
This article provides a risk assessment for Barinthus Biotherapeutics PLC (BRNS), noting its current score of 1.98, ranking 247 out of 386 in the Biotechnology & Medical Research industry. The company's beta value is -0.39, indicating it tends to underperform in rising markets but …
Barinthus Biotherapeutics PLC (BRNS) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 10.63% quarter-over-quarter to 40.87%. James Simons is the largest institutional shareholder, holding 0.37% of …
This article provides an overview of Barinthus Biotherapeutics PLC's (BRNS) dividend history and stock splits. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing and market capitalization information for BRNS.
This article provides a detailed quarterly and annual cash flow statement for Barinthus Biotherapeutics PLC (BRNS), covering operating, investing, and financing activities from FY2020Q1 to FY2026Q1. It includes key financial figures such as net income, changes in working capital, capital expenditures, and free cash …
This page provides financial information for Barinthus Biotherapeutics plc Sponsored ADR (2AB) on Gettex, indicating no current trading activity. It lists various financial data points like statements, statistics, dividends, earnings, and segment performance. The content appears to be a stub or an informational page …
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company focused on developing immunotherapies and vaccines. The article provides current stock price data, historical performance, key financial metrics, and analyst ratings, indicating a buy recommendation with a target price of $5.50. The company is developing treatments …
Barinthus Biotherapeutics PLC (BRNS) is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The company's stock is currently priced at $0.602, with its valuation considered fairly valued among biotechnology peers, and analysts rate it as a "Buy" …
Search by ticker symbol or company name and select a result to open its chart.